Bristol-myers Squibb Compnay

Dana-farber-cancer Institute Inc.

Other

Aldo M Roccaro

Irene M Ghobrial

Josephine M Cardarelli

Antonio Sacco

Kenneth Carl Anderson

Michael A Palladino

Dharminder Chauhan

Salomon Manier

The present disclosure provides a method for treating a subject afflicted with Waldenstr&#xf6;m's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.

Treatment of-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody

The present disclosure provides a method for treating a subject afflicted with Waldenstrm's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.

Treatment of C1013G/CXCR4-associated waldenstro&#xf6;m's macroglobulinemia with an anti-CXCR4 antibody

This invention is based, at least in part, on the finding that certain microRNAs (miRNAs) are expressed at higher or lower levels in circulating exosonies or peripheral blood of subjects with hematological malignancies compared to the level of expression in subjects who do not have the hematological malignancy. In addition, this invention is based, at least in part, on the finding that certain miRNAs are differentially expressed at different stages of a hematological malignancy permitting identification of the stage of the hematological malignancy in a subject. The differential expression of miRNAs at different stages of a hematological malignancy also permits determination of the effectiveness of treatments administered to a subject at the particular stage of the hematological malignancy.

Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies

Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.

Growing community of inventors

Boston, MA, United States of America

Aldo M Roccaro